Literature DB >> 3962865

Comparison of exercise and ajmaline tests with electrophysiologic study in the Wolff-Parkinson-White syndrome.

Y Eshchar, B Belhassen, S Laniado.   

Abstract

Ajmaline test (50 mg intravenously over 1 minute) and ergometric exercise test were performed in 24 patients with the Wolff-Parkinson-White syndrome. The effects of both tests on the conduction in the accessory pathway (AP) were correlated with the anterograde effective refractory period (ERP) of the AP. Ajmaline caused transient anterograde block in the AP in 15 patients, 14 with an ERP of more than 250 ms and 1 with an ERP of 250 ms. Ajmaline failed to abolish preexcitation in 9 patients, all with ERP of the AP of 250 ms or less. Exercise testing caused anterograde block in the AP in 5 patients, in 2 during exercise (ERP of 340 and 360 ms) and in the remaining 3 patients during the recovery phase (ERP of 600, 520 and 460 ms). Of the 10 patients with an ERP of 250 ms or less, ajmaline did not abolish preexcitation in 9 and exercise did not abolish it in any of them. Of the 7 patients with an ERP of 330 ms or more, ajmaline abolished preexcitation in 7 and exercise abolished it in 5 patients. Of the 7 patients with ERP of the AP more than 250 ms but less than 330 ms, ajmaline but not exercise abolished preexcitation in all. Thus, ajmaline and exercise testing can detect patients with short and long ERPs of the AP, respectively, and the effects of ajmaline and exercise tests combined may be useful in the noninvasive assessment of various ranges of ERP of the AP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3962865     DOI: 10.1016/0002-9149(86)90613-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Current management of the Wolff-Parkinson-White syndrome.

Authors:  A Arai; J Kron
Journal:  West J Med       Date:  1990-04

2.  Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action.

Authors:  Claudia Kiesecker; Edgar Zitron; Sonja Lück; Ramona Bloehs; Eberhard P Scholz; Sven Kathöfer; Dierk Thomas; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-30       Impact factor: 3.000

Review 3.  Should patients with asymptomatic wolff-parkinson-white pattern undergo a catheter ablation?

Authors:  P LeLorier; G J Klein; A Krahn; R Yee; A Skanes
Journal:  Curr Cardiol Rep       Date:  2001-07       Impact factor: 2.931

Review 4.  Wolff-Parkinson-White syndrome. Identification and management.

Authors:  F Gaita; C Giustetto; R Riccardi; A Brusca
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.